The global deep brain stimulation (DBS) devices market [NB1] is experiencing remarkable expansion, with projections indicating a growth from USD 1.53 billion in 2024 to an estimated USD 4.37 billion by 2031, reflecting a compound annual growth rate (CAGR) of 13.2% during the forecast period.
Rising Prevalence of Neurological Disorders Drives Market Demand
One major factor driving the demand for DBS devices is the rising prevalence of neurological conditions like depression, epilepsy, and Parkinson’s disease.
For instance, according to the World Stroke Organization (WSO) Global Stroke Fact Sheet for 2022, more than 12.2 million new stroke cases are reported across the globe every year.
This alarming number highlights the growing burden of neurological disorders, significantly driving the demand for advanced treatment solutions and rehabilitation services, particularly in the healthcare and medical device sectors.
The increasing prevalence of stroke cases globally is further expected to accelerate the adoption of innovative surgical techniques, orthopedic implants, and supportive care devices, contributing to market growth.
Parkinson’s disease, a significant public health issue affecting more than six million individuals worldwide, currently necessitates urgent attention. The efficacy of Deep Brain Stimulation (DBS) therapy in managing symptoms of the disease has been substantiated, with approximately 30% of patients experiencing improvements. The introduction of innovative technologies, encompassing surgical instruments, wearable diagnostic systems, and neurostimulation apparatuses, is anticipated to transform patient care. These advancements are primarily designed to enhance patients’ quality of life, but they also present lucrative prospects for medical device manufacturers and healthcare providers in the international market.
Technological Innovations Enhance Treatment Efficacy
DBS technological developments are greatly enhancing patient outcomes. By modifying stimulation parameters in response to real-time brain activity, adaptive DBS systems, for example, maximize therapeutic benefits and reduce adverse effects. Comparing adaptive DBS to traditional DBS techniques, a clinical trial showed that the former could cut motor symptoms in half. Furthermore, the incorporation of machine learning and artificial intelligence (AI) into DBS programming has improved patient outcomes by 20%, highlighting the importance of technology in personalized medicine.
In January 2025, a significant breakthrough in the treatment of movement disorders was announced, as neurologists from The University of Texas Health Science Center at San Antonio became among the first in the U.S. to utilize advanced technology enabling adaptive deep brain stimulation (DBS).
This innovative approach allows the DBS system to automatically adjust stimulation levels in real-time, responding to fluctuations in a patient’s symptoms. This development marks a transformative step in managing conditions like Parkinson’s disease and essential tremor, offering patients more personalized and effective symptom control while enhancing their quality of life.
Advancing Deep Brain Stimulation: The Latest Innovations in Parkinson’s disease Treatment
· Medtronic’s Adaptive “Closed-Loop” Deep Brain Stimulation
Medtronic’s Adaptive “Closed-Loop” Deep Brain Stimulation (DBS) system was approved by the FDA, marking a significant advancement in the treatment of Parkinson’s disease. With the help of BrainSenseTM, this cutting-edge technology enables constant brain signal monitoring and automatically modifies stimulation levels in response to the patient’s current symptoms. Medtronic’s adaptive DBS responds dynamically to changes in symptoms like tremors, rigidity, and slowness, in contrast to traditional DBS systems that provide continuous stimulation. This allows patients to experience more individualized treatment, smoother symptom control, and fewer motor fluctuations.
· Remote Programming with Abbott’s DBS Technology
Abbott’s system now offers remote DBS programming, which is another noteworthy innovation. Neurologists can remotely modify DBS settings with telehealth-based programming, doing away with the need for frequent in-person visits. Patients who live in remote areas or find it difficult to travel because of their Parkinson’s symptoms will particularly benefit from this. Thanks to this development, patients can now adjust their DBS from the comfort of their homes, eliminating the need for them to travel great distances for routine adjustments. In addition to improving accessibility, this innovation guarantees that patients receive prompt, high-quality care as their symptoms change.
· More Precise Stimulation with Boston Scientific’s DBS System
Boston Scientific’s latest device, which has more stimulation contacts than any other system, has advanced DBS customization. With more metal contact points at the end of the DBS lead, stimulation can be precisely directed to the brain’s most advantageous regions while avoiding potentially harmful structures. We can better customize DBS therapy for each patient thanks to this fine-tuned control, which maximizes symptom relief while reducing side effects like muscle contractions or speech difficulties. More accurate stimulation improves our patients’ quality of life and long-term results,
Regulatory Approvals and Market Expansion
Global regulatory entities have progressively recognized the efficiency of Deep Brain Stimulation (DBS) apparatuses, thereby encouraging more approvals and propelling market expansion at an accelerated pace. In February 2025, a significant instance of this trend materialized when the United States Food and Drug Administration (FDA) endorsed Medtronic’s advanced DBS system for the management of Parkinson’s disease. This approval serves as a pivotal moment in the development of DBS therapy and is expected to substantially stimulate market growth, particularly in areas featuring sophisticated healthcare infrastructure and increasing acceptance of sophisticated neurological treatment methods.
Challenges and Opportunities in Emerging Markets
Even with the Deep Brain Stimulation (DBS) market’s encouraging growth trajectory, some obstacles still prevent widespread adoption. Particularly in low- and middle-income areas, high treatment costs and the need for highly skilled surgeons continue to be major obstacles. These elements lead to inequities in the availability of treatments and restrict patient access. The situation is quickly changing, though, as emerging markets present significant growth prospects. Future market expansion for DBS device manufacturers in these areas is anticipated to be fueled by the emergence of a growing middle class, growing healthcare infrastructure, and growing government attention to neurological care.
Key Market Players and Strategic Developments
To increase their market presence, top companies in the DBS device market are actively pursuing strategic initiatives. For instance, in August 2022, Medtronic introduced the SenSight directional lead system, aiming to improve the management of epilepsy and movement disorders. In a similar vein, the Abbott Infinity Deep Brain Stimulation (DBS) system, developed by St. Jude Medical and later acquired by Abbott, received FDA approval in 2016. By diverting stimulation away from delicate brain regions, the directional lead technology in this system minimizes side effects and enables precise control of symptoms. Together, these businesses control the majority of the market and set the direction of the sector. Boston Scientific Corporation, Abbott, Medtronic, Aleva Neurotherapeutics S.A., Nexstim, LivaNova PLC, NeuroPace Inc.
About Author:
HTF Market Intelligence Consulting is uniquely positioned to empower and inspire with research and consulting services to empower businesses with growth strategies, by offering services with extraordinary depth and breadth of thought leadership, research, tools, events, and experience that assist in decision-making.
